Description
M7824 is a bifunctional fusion protein that combines anti-PD-L1 and TGF-beta receptor II components in a single therapeutic agent. Based on clinical trial data, this compound targets dual immune checkpoint pathways and has been evaluated in combination with HPV vaccines for various solid tumors including colorectal cancer. The drug represents a novel approach to overcoming immune suppression by simultaneously blocking PD-L1 mediated immune evasion and neutralizing TGF-beta signaling.
Mechanism of Action
M7824 functions through dual mechanisms by binding to PD-L1 on tumor cells to prevent T-cell exhaustion while simultaneously trapping TGF-beta in the tumor microenvironment. This bifunctional approach addresses two major immunosuppressive pathways that allow tumors to evade immune surveillance, potentially enhancing anti-tumor immune responses more effectively than single-target therapies.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.